Introduction {#sec1-1}
============

Alzheimer\'s disease (AD) is an irreversible neurodegenerative disease induced by multiple complex mechanisms. Its pathogenesis involves abnormal tau protein expression, nerve cell apoptosis, genetic associations, and abnormal mitochondria.\[[@ref1][@ref2]\] AD can not only seriously jeopardize the health of the elderly but also impose a great burden on families and society and grow with age. The total number of patients with AD worldwide in 2016 was about 35 million, which is expected to reach 65.7 million in 2030 and 115.4 million in 2050.\[[@ref3]\] At present, AD can only be treated symptomatically, delaying its development; a treatment strategy to cure AD remains lacking to date.\[[@ref4]\] Anti-AD drug N-methyl-D-aspartate receptor (NMDAR) blockers and acetylcholinesterase inhibitors approved by the US Food and Drug Administration can only delay symptoms but cannot alleviate or reverse pathological processes.\[[@ref5]\] Therefore, the development of anti-AD drugs still has patient needs and market demand.

Many anti-AD drugs against a single target have failed in phase III clinical trials, indicating that drug research should shift to multi-component, multi-target, and multi-pathway. The pharmacological activity characteristics of multi-target natural products render them uniquely advantageous compared with Western medicine.\[[@ref6]\] *Schisandra chinensis* of the Magnoliaceae family is a type of dry and mature fruit. It is a common Chinese herbal medicine with the bioactivities of astringents, benefiting qi for promoting the production of tranquilizers in official Chinese Pharmacopeia.\[[@ref7]\] The main pharmacologically active ingredients in *S. chinensis* are dibenzocyclooctadiene lignans. Modern pharmacological studies showed that *S. chinensis* has multiple bioactivities,\[[@ref8]\] such as anti-inflammatory,\[[@ref9]\] antioxidative,\[[@ref10]\] and anticancer.\[[@ref11]\] It can also influence the central nervous system.\[[@ref12]\] Related studies confirmed the neuroprotective and anti-AD effects of *S. chinensis*.\[[@ref13][@ref14][@ref15]\] However, the active ingredient in *S. chinensis* and its specific target remain to be determined. To solve these problems, we applied network pharmacology, which has been widely used in the discovery and development of drugs to understand the treatment, the nature of Chinese medicine, and the role of prescriptions.\[[@ref16][@ref17]\]

In summary, the chemical constituents of *S. chinensis* and their target were analyzed using a network pharmacology method and bioinformatics analysis to explain the potential mechanism by which *S. chinensis* treats AD. Finally, the results were verified by *in vitro* cell experiments.

Materials and Methods {#sec1-2}
=====================

Materials {#sec2-1}
---------

1-Phenyl-1,3-Butanedion and nootkatone (\>99% purity) (NOT) were purchased from Sigma-Aldrich (St. Louis, MO, USA), (E)-9-Isopropyl-6-Methyl-5 and 9-Decadiene-2-One (\>98% purity) were brought from Servicebio (Hangzhou, China). PC12 cells, dimethyl sulfoxide (DMSO), Dulbecco\'s modified Eagle\'s medium (DMEM), fetal bovine serum, and 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Servicebio (Hangzhou, China). The kits for determining nitric oxide (NO), lactate dehydrogenase (LDH), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) were obtained from Nanjing Jiancheng Institute of Biological Engineering (Nanjing, China). All antibodies were obtained from Abcam (Cambridge, UK). Other chemicals and materials were purchased from Servicebio (Hangzhou, China).

Database building {#sec2-2}
-----------------

The active ingredients and targets of *S. chinensis* were collected from BATMAN-TCM ([http://bionet. ncpsb. org/batman-tcm/](http://bionet.ncpsb.org/batman-tcm/)).\[[@ref18]\] First, we opened the website according to the previous URL and selected a and enter the Latin name of the medicinal material *S. chinensis*, other settings selected default, then started running the program. Finally, after a few seconds, you would be able to download the compound and target from download all the target prediction results. All setting parameters and operation steps are executed according to the manual.

ADMET and toxicity analysis of the active ingredients {#sec2-3}
-----------------------------------------------------

After obtaining the active constituents and targets of *S. chinensis* in the treatment of nervous system diseases and AD from BATMAN-TCM, we screened compounds that they could regulated nervous system diseases and AD. Then, ADMET and toxicity analysis of these compounds were tested by the discovery studio 4.0. First, we converted all the compounds into sdf format and imported them into the software. Next, we chose the calculate molecular properties module under the small molecule interface, we used the AMET descriptors in it for filtering compounds, and all parameters were default. All setting parameters and operation steps are executed according to the manual.

Bioinformatics analysis {#sec2-4}
-----------------------

According to the result of ADMET and toxicity analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) enrichment analyses of the targets of these compounds were performed using DAVID 6.7 (<https://david.ncifcrf.gov/>).\[[@ref19]\] First, the obtained targets were imported into the DAVID database, and then the species selected humans. Finally, the obtained data were sequentially analyzed using KEGG and GO options. All setting parameters and operation steps are executed according to the manual.

Network conduction and analysis {#sec2-5}
-------------------------------

To determine the complex relationship between *S. chinensis* and AD, we constructed a network of compound--target--disease relationships by Cytoscape 3.7.1.\[[@ref20]\] First, we processed the target and compound for the disease in excel, then they were imported them into the software, and all parameters used default settings. All setting parameters and operation steps are executed according to the manual.

Protein-protein interaction analysis {#sec2-6}
------------------------------------

To identify key proteins, we further constructed a protein--protein interaction network by STRING 10.5 (<https://string-db.org/>). First, we selected the multiple proteins option in the URL interface, then entered the protein into the box on the right, and the species selected humans. Finally, all parameters selected the default settings to get the results. All setting parameters and operation steps are executed according to the manual.

Cells culture {#sec2-7}
-------------

PC12 cells were cultured at 5% CO~2~ in air and 37°C in 25 cm^2^ flasks containing DMEM supplemented with 15% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin.

3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetra zolium bromide assay {#sec2-8}
------------------------------------------------------------------

Cell viability was analyzed using the MTT assay. First, PC12 cells were seeded at a density of 10^4^ cells/well and then cultured in complete medium for 24 h in 96-well plates. Then, 6.25, 12.5, 25, and 50 μg/mL NOT were incubated for 12 h. After incubation with 20 μM Aβ~1-42~ for 24 h (model group), the cells were added with 50 μg of MTT in each hole and incubated for 4 h at 37°C. Finally, the cells removed from the medium were dissolved in 200 μL of DMSO for 10 min, and the absorbance at 570 nm was recorded with a microplate reader (Infinite M1000, Tecan, Sunrise, Austria). What\'s more, we also tested the activity of (E)-9-Isopropyl-6-Methyl-5,9-Decadiene-2-One, 1-Phenyl-1,3-Butanedion and phenyl-2-Propanone by the MTT.

Lactate dehydrogenase levels, nitric oxide levels and glutathione peroxidase, and superoxide dismutase activities analysis {#sec2-9}
--------------------------------------------------------------------------------------------------------------------------

PC12 cells were cultured at 10^4^ cells/well in 6-well plates for 24 h. The cells were pre-incubated with or without 25 μg/mL NOT for 12 h, followed by 20 μM Aβ~1-42~ for 24 h. The supernatant was collected for the following experiments. NO levels, GSH-Px activities, SOD activities, and LDH release were analyzed using commercial kits in accordance with the manufacturer\'s instructions.

Western blot assay {#sec2-10}
------------------

PC12 cells were cultured in 75 cm^2^ flasks. After being incubated with 25 μg/mL NOT and 20 μM Aβ~1-42~, the cells were collected for total protein extraction, and the protein concentration was determined by BCA assay kit. Then, 30 μg protein was separated by 12% sodium dodecyl sulfate poly-acrylamide gel electrophoresis gels. Afterward, they were transferred onto 0.22 μm NC membranes and then blocked with 5% (w/v) nonfat milk in PBST for 2 h. All primary antibodies were incubated at 4°C overnight, and the secondary antibodies were incubated at room temperature for 2 h. Finally, the ECL plus kit was used to detect the protein bands.

Statistical analysis {#sec2-11}
--------------------

All data were presented as mean ± standard deviation, and each experiment was repeated at least three times. Significant differences were compared using one-way ANOVA or Dunnett\'s test. Statistical significance was considered at *P* \< 0.05.

Results {#sec1-3}
=======

Collection of compounds and targets from *Schisandra chinensis* {#sec2-12}
---------------------------------------------------------------

Through the BATMAN-TCM database, 175 chemical constituents of *S. chinensis* were collected, but 63 species had no structural information. To further investigate the targets of these compounds, we set the parameters as follows: predicted candidate targets with scores not smaller than score cutoff = 20 for each ingredient, adjusted *P* ≤ 0.05 were highlighted in the results. Finally, 134 potential targets related to the nervous system and AD were screened in accordance with the disease classification of the medical subject vocabulary. Moreover, we further carried out ADMET and toxicity analysis of the active ingredients related to the 134 targets. As shown in [Figure 1](#F1){ref-type="fig"}, four compounds had no good metabolic activity, they were epiguaipyridine, clupanodonic acid, Vitamin K1 and nonylphenol. Luckily, the four compounds regulated more targets had a good metabolic activity which were marked by yellow. Thus, we finally got 132 targets related to nervous system diseases and AD \[[Supplementary Material 1](#App1){ref-type="app"}\].

![ADMET and toxicity analysis of the active ingredients which come from *Schisandra chinensis* on nervous system diseases and Alzheimer\'s disease](IJPharm-52-94-g001){#F1}

Bioinformatics analyses of potential targets {#sec2-13}
--------------------------------------------

The 132 targets obtained from the above analysis were imported into the DAVID database for GO annotation and KEGG enrichment analysis. The results of GO annotation indicated that the most relevant functions involved in these targets were acetylcholine regulation and ion channel, which are the main pathological processes of AD \[[Supplementary Material 2](#App2){ref-type="app"}\]. KEGG analysis showed that the pathways involved are nicotine addiction, retrograde endocannabinoid signaling, GABAergic synapse, and morphine addiction. One of the results was especially noticeable because these proteins can significantly enrich the AD pathway \[[Figure 2](#F2){ref-type="fig"}\]. As shown in [Figure 2](#F2){ref-type="fig"}, *S. chinensis* can regulate the calcium signaling pathway by controlling Apoe, NMDAR, VDCC, and NOS, thereby exerting anti-oxidative and anti-apoptotic effects, which are important for AD treatment.

![Regulation of *Schisandra chinensis* on Alzheimer\'s disease signaling pathway. Red stars represented key protein](IJPharm-52-94-g002){#F2}

Network construction and analysis {#sec2-14}
---------------------------------

KEGG and disease enrichment analyses revealed that *S. chinensis* treats AD by controlling 33 key proteins. We also found 39 compounds corresponding to the 33 proteins from the BATMAN-TCM database. A chemical disease--target--compound network was constructed using the Cytoscape 3.7.1 software \[[Figure 3](#F3){ref-type="fig"}\]. Statistical analysis showed that (E)-9-isopropyl-6-methyl-5,9-decadiene-2-one, 1-phenyl-1,3-butanedion, nootkatone, and phenyl-2-propanone can regulate more targets, and APOE, CACNA1D, GRIN2A, and PTGS2 were the most active proteins. Moreover, protein--protein interaction analysis showed that NOS1 was the most critical protein \[[Supplementary Material 3](#App3){ref-type="app"}\].

![Disease--target--compound network of major targets regulated by *Schisandra chinensis* active ingredients. Red represents disease, blue represents key proteins, and green represents active ingredients](IJPharm-52-94-g003){#F3}

Effects of the representative ingredient of *Schisandra chinensis* on the Aβ~1-42~-induced PC12 cells injury {#sec2-15}
------------------------------------------------------------------------------------------------------------

The survival rate and LDH activity of PC12 cells in each group were compared. Compared with that in the control group, the survival rate of PC12 cells in the model group was significantly lower, but the survival rates of the cells in the 12.5, 25, and 50 μg/mL NOT groups were significantly higher. Notably, 25 μg/mL NOT exerted the greatest protective effect \[[Figure 4a](#F4){ref-type="fig"}\]. LDH is normally present in cells and leaks during necrosis or apoptosis. Compared with that in the control group, the LDH activity in the model group was significantly higher, whereas that in the 25 μg/mL NOT group was significantly lower \[[Figure 4b](#F4){ref-type="fig"}\].

![Effects of the representative ingredient of *Schisandra. chinensis* on the Aβ~1-42~-induced PC12 cells injury. (a) 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay of incubation with NOT on the Aβ~1-42~-induced PC12 cells injury. (b) Lactate dehydrogenase release in the cell supernatant. (c) 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay of incubation with (E)-9-isopropyl-6-methyl-5,9-decadiene-2-one on the Aβ~1-42~-induced PC12 cells injury. (d) 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay of incubation with 1-phenyl-1,3-butanedion on the Aβ~1-42~-induced PC12 cells injury. (e) 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay of incubation with phenyl-2-propanone on the Aβ~1-42~-induced PC12 cells injury. ^\#\#\#^*P* \< 0.001 versus control, \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 versus model](IJPharm-52-94-g004){#F4}

Meanwhile, we tested the another three the representative ingredient of *S. chinensis* on AD, the results of MTT showed that they could protect PC12 cells on the Aβ~1-42~-induced injury \[Figure [4c](#F4){ref-type="fig"}-[e](#F4){ref-type="fig"}\].

Effects of NOT on nitric oxide level, superoxide dismutase activity, and glutathione peroxidase activity in PC12 cells with Aβ~1-42~-induced injury {#sec2-16}
---------------------------------------------------------------------------------------------------------------------------------------------------

Compared with those in the control group, the SOD and GSH-Px activities in the PC12 cells of the model group significantly decreased \[Figure [5b](#F5){ref-type="fig"} and [c](#F5){ref-type="fig"}\], whereas the NO level significantly increased \[[Figure 5a](#F5){ref-type="fig"}\]. However, the SOD and GSH-Px activities in the 25 μg/mL NOT group significantly increased and the NO levels significantly decreased in the PC12 cells with Aβ~1-42~-induced injury compared with the model group \[[Figure 5](#F5){ref-type="fig"}\].

![Effects of NOT on the levels of nitric oxide, activity of superoxide dismutase and glutathione peroxidase in Aβ1-42-induced PC12 cells injury. (a) Effect of NOT on the nitric oxide level in PC12 cells. (b) Effect of NOT on the superoxide dismutase activity in PC12 cells. (c) Effect of NOT on the superoxide dismutase activity in PC12 cells. ^\#\#\#^*P* \< 0.001 versus control, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 versus model](IJPharm-52-94-g005){#F5}

Effects of NOT regulated HO-1 and cleaved caspase-3 levels in PC12 cells with Aβ~1-42~-induced injury {#sec2-17}
-----------------------------------------------------------------------------------------------------

Compared with those in the control group, the expression levels of HO-1 and cleaved caspase-3 protein in the model group were significantly higher \[Figure [6a](#F6){ref-type="fig"}-[c](#F6){ref-type="fig"}\]. By contrast, the expression levels of HO-1 and Bax protein in the 25 μg/mL NOT group were significantly lower than those in the model group \[[Figure 6](#F6){ref-type="fig"}\].

![Effects of NOT on the expressions of HO-1 and cleaved caspase-3 protein in PC12 cells. (a) HO-1 and cleaved caspase-3 protein expressions. (b) Quantitative analysis of HO-1 level in PC12 cells. (c) Quantitative analysis of cleaved caspase-3 level in PC12 cells. ^\#\#\#^*P* \< 0.001 versus control, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 versus model](IJPharm-52-94-g006){#F6}

Discussion {#sec1-4}
==========

*S. chinensis* is a member of the Magnoliaceae family, and its main drug site is its mature fruit. *S. chinensis* has diverse activities, such as anti-inflammatory, anti-oxidative, anti-viral, vasodilating, neuroprotective, and anti-ulcer.\[[@ref8][@ref13][@ref21]\] It is mainly used to treat nephropathy and encephalopathy in traditional medicine, and its main pharmacodynamic effect is conferred by its complex composition. As a result, the potential mechanisms of *S. chinensis* remain unclear to date. Network pharmacology analyzes the relationship between drugs and targets from a holistic and systematic perspective, and it can predict the pharmacodynamic effects of the active ingredients of traditional Chinese medicine. Therefore, we used network pharmacology to construct a compound--gene--disease network of the main components of *S. chinensis*, analyzed the biological functions of each pathway, and classified it. We formulated a hypothesis about the main pharmacodynamic effects of *S. chinensis* in preventing AD and performed cell experiments to confirm the results *in vitro*.

Network pharmacology analyzes the relationship among drugs, targets, and diseases by constructing a network model. It is a new model for drug research. On the basis of existing data in the database, a drug--target--disease network for specific drugs is established, and then the drug is analyzed. The intervention and influence of the disease network can predict the effects of pharmacodynamic components on certain key targets and their pathways.\[[@ref22]\] The composition of traditional Chinese medicines is diverse, and complex network relationships also exist between diseases and targets. Therefore, network pharmacology is suitable for elucidating the mechanism of traditional Chinese medicine. In the present study, 175 compounds of *S. chinensis* and 134 nervous system and AD hippocampal targets were collected from the BATMAN-TCM database, and then, ADMET and toxicity analysis of the potential active ingredient were finished by discovery studio 4.0, the targets related to active ingredient were imported into the DAVID database for GO annotation and KEGG enrichment analysis. Finally, we obtained 39 active components of *S. chinensis* to regulate 33 related targets for AD. Furthermore, a component--gene--disease network was constructed. Network analysis showed that (E)-9-isopropyl-6-methyl-5,9-decadiene-2-one and NOT were the compounds that regulated the most targets, and CACNA1D and GRIN2A were the most regulated targets. Moreover, protein--protein interaction analysis revealed that NOS1 was the most critical protein. KEGG function enrichment analysis showed that the active ingredients of *S. chinensis* treat AD by regulating the calcium signaling pathway. This result is consistent with the pathology of AD.\[[@ref23][@ref24]\] However, an interesting phenomenon was that we had not enriched the targets regulated by lignin compounds, but there were many reports that lignin compounds in *S. chinensis* had anti-AD effects, such as schizandrin B, schisantherin A, and lignans. To explain this phenomenon, we further looked at the raw data of the analysis. We found that this was related to the threshold set during protein screening. If we lowered the current standard, lignin compounds in *S. chinensis* could be enriched to the target related to against AD.

AD is a progressive neurodegenerative disease where progressive decline occurs after intelligence reaches normal levels. Although the molecular biology of AD has been researched since the 1980s, the cause remains unclear. Calcium overload is reportedly the main cause of AD pathogenesis.\[[@ref23][@ref24]\] Neurons with near amyloid deposits have higher Ca^2+^ levels than normal resting levels, and the environment of elevated resting Ca^2+^ promotes negative plasticity.\[[@ref25][@ref26]\] This mechanism increases the expression and activity of calcineurin (CaN) by elevating intracellular levels. CaN is a Ca^2+^ signaling protein activated by calmodulin (CaM), which is sensitive to subtle rises in intracellular Ca^2+^ levels. Activated CaN activates additional phosphatases,\[[@ref27]\] such as PP1. Then, CaMKII holenzymes can be activated upon the binding of Ca2+/CaM. The elevated intracellular Ca^2+^ levels could initiate a series of harmful processes, including further promotion of free radical growth, destruction of cell membranes and skeletons, and sequential activation of Ca^2+^-dependent kinases, lipases, and proteases, which lead to cell damage and even death.\[[@ref28]\] Our experiment showed that NOT reduced apoptosis and LDH level in PC12 cells with Aβ~1-42~-induced injury, reduced the secretion of NO, enhanced the activities of SOD and GSH-Px, and reversed the expression of HO-1 and cleaved caspase-3, which are closely related to the calcium signaling pathway in AD. The results also corroborated the anti-AD effect of *S. chinensis* in treating AD and the correctness of previous results.\[[@ref13][@ref21][@ref29]\]

However, this study has some limitations. For example, this conclusion needs to be further verified *in vivo*, and additional inhibitors must be included to reverse verification. In addition, it also requires the addition of pharmacokinetic experiments to confirm the blood components.

Conclusions {#sec1-5}
===========

To the best of our knowledge, this research provided the first network pharmacology evidence that *S. chinensis* protects and treats AD through the Ca^2+^ signaling pathway by exerting anti-apoptotic and anti-oxidant activities and lowering NO level. Moreover, network pharmacologyin vitro showed that the active ingredients from *S. chinensis* can protect PC12 cells against Aβ~1-42~-induced apoptosis. This study may serve as a reference in developing *S. chinensis* as a complementary and alternative medicine to treat AD.
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  ------------- -------- --------- ---------
  Target name   CHRNB2   GRIA4     KCNJ9
  ACHE          CHRNB4   GRIK2     KCNQ1
  ADRBK1        CNR1     GRIN1     MAOA
  ALOX15        COMT     GRIN2A    MAOB
  ALOX15B       CPLX2    GRIN2B    MAP2K5
  ALOX5         CRH      GRIN2C    MPO
  APOE          DDC      GRIN2D    
  ARRB2         DLG4     GRIN3A    NGFR
  BAX           DNM3     GRIN3B    NOS1
  BCHE          DRD1     GSK3A     PPP2CA
  BCL2          DRD2     GUCY1B3   PPP2CB
  BDKRB2        DRD3     HAP1      PPP3CA
  CACNA1A       DRD4     HOMER1    PPP3CB
  CACNA1C       DRD5     HTR1A     PPP3R1
  CACNA1D       FASLG    HTR1B     PRKCD
  CACNA1S       GABRA1   HTR2A     PTGS1
  CALM1         GABRA2   HTR2B     PTGS2
  CALM2         GABRA3   HTR2C     RAB3A
  CALM3         GABRA4   HTR3A     RYR1
  CALML3        GABRA5   HTR3B     SCN1A
  CAMK2D        GABRA6   HTR3C     SHANK3
  CAMK2G        GABRB1   HTR3D     SLC17A7
  CDC42         GABRB2   HTR3E     SLC18A2
  CHRFAM7A      GABRB3   HTR4      SLC18A3
  CHRM1         GABRD    HTR6      SLC5A7
  CHRM2         GABRE    HTR7      SLC6A3
  CHRM3         GABRG1   IGF1      SLC6A4
  CHRM4         GABRG2   ITPR1     SRC
  CHRM5         GABRG3   ITPR2     STX1A
  CHRNA3        GABRP    ITPR3     STX3
  CHRNA4        GABRQ    KCND2     TH
  CHRNA6        GRIA1    KCNJ3     TPH1
  CHRNA7        GRIA2    KCNJ5     YWHAE
  ------------- -------- --------- ---------
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